Alzheimer's Patients Deserve a Chance
The Centers for Medicaid and Medicare Services (CMS) has proposed a new Medicare coverage decision that effectively would block millions of Americans from getting access to life-changing treatments to treat Alzheimer's.
What this new draft proposal would actually do is create barriers to FDA approved therapies for people who have historically been excluded from clinical trials, including African Americans, Latinos, and low-income families.
Unless this proposal is reversed and Medicare covers these treatments, there will be little access and no hope for people in the early stages of Alzheimer's who wants to slow the progression of this disease.
We can't let this happen. We're not giving up.
Will you reach out now to your member of Congress and the White House?
Together we can stand up against CMS's decision that would create further discrimination in an already inequitable health care system.
Sign PetitionSign Petition
Dear [elected official],
As your constituent, I am outraged by the Centers for Medicare and Medicaid Services (CMS) recent draft proposal to restrict access to an entire class of Alzheimer's treatments and am calling on you to address it.
CMS has proposed to limit Medicare coverage for U.S. Food and Drug Administration (FDA) approved monoclonal antibodies that target amyloid proteins for the treatment of Alzheimer's disease only to Medicare recipients who are enrolled in hard-to-access clinical trials.
This proposal would severely restrict treatment access for Alzheimer's patients, many of whom are African American and Latino, to a promising new class of drugs which researchers and physicians are currently depending on to help mitigate the impact of Alzheimer's on American families.
I am asking you to tell CMS to eliminate barriers and, instead, authorize Medicare reimbursement to cover this class of Alzheimer's treatments. This will help ensure access to FDA approved therapies to all people, including Latino and African American people at greater risk of Alzheimer's.